1-3 of 3
Giovanni Longo, MD
Close
Sort by
Journal Articles

High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.

Barbara Scappini, MD, Giacomo Gianfaldoni, MD, Palmieri Salvatore, MD, Maria Chiara Susini, MD, Teresa Izzo, MD, Francesco Mannelli, MD, Giovanni Longo, MD, Rosa Fanci, MD, Felicetto Ferrara, MD, Alberto Bosi, MD
Journal: Blood
Blood (2009) 114 (22): 1060.
https://doi.org/10.1182/blood.V114.22.1060.1060
Published: 2009
Journal Articles

Clinical Relevance of JAK2 V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis

Paola Guglielmelli, MD, Giovanni Barosi, MD, Alessandro Pancrazzi, PhD, Giovanni Longo, MD, Elisabetta Antonioli, MD, Lisa Pieri, MD, Flavia Biamonte, BiSci, Vanessa Ponziani, PhD, Alessandro Rambaldi, Alberto Bosi, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2008) 112 (11): 2799.
https://doi.org/10.1182/blood.V112.11.2799.2799
Published: 2008
Journal Articles

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Luigi Rigacci, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Varesco Martini, MD, Paolo Bernardeschi, MD, Giovanni Longo, MD, Alberto Bosi, MD
Journal: Blood
Blood (2004) 104 (11): 4577.
https://doi.org/10.1182/blood.V104.11.4577.4577
Published: 2004